TPO
Thrombopoietin (TPO)
The primary regulator of platelet production. FDA-approved analogues (Eltrombopag, Romiplostim) are used for immune thrombocytopenia.
Mechanism of Action
TPO binds to MPL receptors on megakaryocyte progenitors, stimulating platelet production. It also has effects on hematopoietic stem cell self-renewal.
Health Claims & Evidence
Stimulates platelet production
Treatment for thrombocytopenia
Supports hematopoietic stem cell self-renewal
Short-Term Effects
Increased platelet count within 1–2 weeks.
Long-Term Effects
Sustained platelet count maintenance with continued use.
Side Effects
Thrombosis risk, bone marrow fibrosis with long-term use.
Contraindications
Use with caution in thrombosis risk.
This profile is provided for educational research only. It is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Verify primary sources and consult a qualified healthcare professional for medical decisions.
Research Papers
Thrombopoietin and platelet production
de Sauvage et al. · Nature · 1994
Educational research only. This profile is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Consult a qualified healthcare professional for medical decisions.
Related Peptides
Explore the research further
Our AI Research Advisor can help you explore the evidence on TPO and related peptides, and prepare an educational research summary.
Explore Research